COMMUNIQUÉS West-GlobeNewswire

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
22/06/2026
As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion 1 . Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the " [...]
Weight Watchers to Support the American Heart Association’s Healthy Living BEYOND Weight Study
22/06/2026
Weight Watchers helps members achieve lasting weight loss through medication, personalized nutrition, and community support. As part of its collaboration with the American Heart Association, Weight Watchers is [...]
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision [...]
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
22/06/2026
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“ [...]
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
22/06/2026
Strong Capitalization Foundation Supports Strategic Growth and Market Stability BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”) today announced that NewGen’s [...]
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated [...]
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it has partnered [...]
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026
FAIR HAVEN, N.J. and ITHACA, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- TETmedical, Inc., a clinical stage medical diagnostics company developing rapid tools for diagnosing acute neurological injury based on its patented [...]
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which [...]
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
22/06/2026
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family [...]
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
22/06/2026
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July [...]
Novo Nordisk A/S - share repurchase programme
22/06/2026
Bagsværd, Denmark, 22 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
22/06/2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026 [...]
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
22/06/2026
– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in- [...]
Communiqué de presse : Sanofi nomme Paulo Fontoura à la tête de sa R&D
22/06/2026
Sanofi nomme Paulo Fontoura à la tête de sa R&D Paris , 22 juin 2026. Sanofi annonce la nomination du Dr Paulo Fontoura au poste de Vice-Président Exécutif, Responsable mondial de la Recherche & Développement [...]
SKG Brings Deep Recovery Technology to Father’s Day Gifting
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- This Father’s Day, SKG is bringing smart recovery to the top of the gift list with wearable smart massagers designed for dads’ everyday routines. As thoughtful gift options, [...]
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
22/06/2026
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development [...]
Clariane has launched a proposed offering of €333 million of undated deeply subordinated hybrid notes to refinance its ODIRNANE
22/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
22/06/2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]

Pages